To evaluate the efficacy of the Defend 1050 / Pro XL at reducing SARS-CoV-2, the virus causing COVID-19.
The challenge pathogen, SARS-CoV-2 USA-CA1/2020, was used for testing the efficacy of the Defend 1050 / Pro XL. The bioaerosol efficacy challenge was completed in three distinct trials with the active pathogen to create a baseline of data. The Defend 1050 / Pro XL was placed in the same position for each viral challenge and operated in the same manner.
Two control tests were conducted without the Defend 1050 / Pro XL in the testing chamber. The control tests were used for the comparative baseline to assess the viral reduction when the Defend 1050 / Pro XL was operated in the challenge trials, to enable net reduction calculations to be made. The device was run at maximum speed (5).
The Defend 1050 / Pro XL achieved a 4.53 log10 reduction, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.
The Defend 1050 / Pro XL performed to manufacturer specifications and demonstrated a dramatic reduction of active virus after 30 minutes of exposure in aerosol form.
Every effort was made to simulate a real-life environment in the chamber while taking into consideration the special precautions needed when working with a Biosafety Level 3 Pathogen. Overall, the Defend 1050 / Pro XL device showed substantial efficacy in the removal of SARS-CoV-2 USA-CA1/2020 out of the breathable air.